MX2016009448A - (hetero)aril-imidazoles/pirazoles para el tratamiento de trastornos neurologicos. - Google Patents
(hetero)aril-imidazoles/pirazoles para el tratamiento de trastornos neurologicos.Info
- Publication number
- MX2016009448A MX2016009448A MX2016009448A MX2016009448A MX2016009448A MX 2016009448 A MX2016009448 A MX 2016009448A MX 2016009448 A MX2016009448 A MX 2016009448A MX 2016009448 A MX2016009448 A MX 2016009448A MX 2016009448 A MX2016009448 A MX 2016009448A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- pyrazoles
- hetero
- neurological disorders
- aryl imidazoles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula I, en la que A, B, X, Z y R1-R6 son como se definieron en las reivindicaciones, para el tratamiento de trastornos neurológicos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14153372 | 2014-01-31 | ||
PCT/EP2015/051638 WO2015113980A1 (en) | 2014-01-31 | 2015-01-28 | (hetero)aryl imidazoles/pyrazoles for treatment of neurological disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016009448A true MX2016009448A (es) | 2016-10-13 |
Family
ID=50028897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016009448A MX2016009448A (es) | 2014-01-31 | 2015-01-28 | (hetero)aril-imidazoles/pirazoles para el tratamiento de trastornos neurologicos. |
Country Status (12)
Country | Link |
---|---|
US (1) | US10399985B2 (es) |
EP (1) | EP3099690B1 (es) |
JP (1) | JP6471169B2 (es) |
KR (1) | KR20160108561A (es) |
CN (1) | CN105899513A (es) |
AR (1) | AR099220A1 (es) |
CA (1) | CA2935065A1 (es) |
HK (1) | HK1223932A1 (es) |
MX (1) | MX2016009448A (es) |
RU (1) | RU2016133624A (es) |
TW (1) | TW201613924A (es) |
WO (1) | WO2015113980A1 (es) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1651251A4 (en) | 2003-07-31 | 2008-06-18 | Bayer Pharmaceuticals Corp | METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS |
US20080090834A1 (en) * | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
WO2010063487A1 (en) * | 2008-12-05 | 2010-06-10 | Merz Pharma Gmbh & Co. Kgaa | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
TW201200516A (en) * | 2009-12-17 | 2012-01-01 | Lundbeck & Co As H | Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors |
US9938269B2 (en) * | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
EP2763533B1 (en) * | 2011-10-06 | 2021-12-29 | Merck Sharp & Dohme Corp. | Triazolyl pde10 inhibitors |
WO2013127817A1 (en) * | 2012-02-27 | 2013-09-06 | H. Lundbeck A/S | Imidazole derivatives as pde10a enzyme inhibitors |
CN104768554B (zh) * | 2012-11-07 | 2018-04-17 | 霍夫曼-拉罗奇有限公司 | 三唑并化合物 |
-
2015
- 2015-01-28 WO PCT/EP2015/051638 patent/WO2015113980A1/en active Application Filing
- 2015-01-28 KR KR1020167023872A patent/KR20160108561A/ko not_active Application Discontinuation
- 2015-01-28 CA CA2935065A patent/CA2935065A1/en not_active Abandoned
- 2015-01-28 EP EP15701365.7A patent/EP3099690B1/en active Active
- 2015-01-28 CN CN201580004114.6A patent/CN105899513A/zh active Pending
- 2015-01-28 MX MX2016009448A patent/MX2016009448A/es active IP Right Grant
- 2015-01-28 JP JP2016549385A patent/JP6471169B2/ja not_active Expired - Fee Related
- 2015-01-28 RU RU2016133624A patent/RU2016133624A/ru unknown
- 2015-01-29 AR ARP150100251A patent/AR099220A1/es unknown
- 2015-01-30 TW TW104103313A patent/TW201613924A/zh unknown
-
2016
- 2016-07-27 US US15/220,617 patent/US10399985B2/en not_active Expired - Fee Related
- 2016-10-25 HK HK16112242.3A patent/HK1223932A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2015113980A1 (en) | 2015-08-06 |
RU2016133624A (ru) | 2018-03-06 |
EP3099690B1 (en) | 2019-08-28 |
JP2017504648A (ja) | 2017-02-09 |
HK1223932A1 (zh) | 2017-08-11 |
AR099220A1 (es) | 2016-07-06 |
CN105899513A (zh) | 2016-08-24 |
TW201613924A (en) | 2016-04-16 |
US20160333018A1 (en) | 2016-11-17 |
JP6471169B2 (ja) | 2019-02-13 |
EP3099690A1 (en) | 2016-12-07 |
CA2935065A1 (en) | 2015-08-06 |
US10399985B2 (en) | 2019-09-03 |
KR20160108561A (ko) | 2016-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA117521C2 (uk) | Заміщені [1,2,4]триазольні та імідазольні сполуки як фунгіциди | |
EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
MX371312B (es) | Pirazolil-ureas como inhibidores de quinasas. | |
MX2016016143A (es) | Compuestos de [1,2,4]triazol sustituido. | |
TW201613886A (en) | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones | |
JO3466B1 (ar) | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 | |
TW201613853A (en) | Synthesis of polycyclic-carbamoylpyridone compounds | |
MX2016016405A (es) | Compuestos de [1,2,4]triazol e imidazol sustituidos como fungicidas. | |
MX2016014857A (es) | Compuestos de [1,2,4]triazol e imidazol sustituidos como fungicidas. | |
MX2017007188A (es) | Compuesto antimicotico. | |
JO3372B1 (ar) | مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية | |
EA201691999A1 (ru) | Новые сульфониламинобензамидные соединения | |
SG10201900954SA (en) | Heterocycles as Modulators of Kinase Activity | |
MX2017011389A (es) | Proceso para la preparacion de 3-cloro-2-vinilfenilsulfonatos. | |
NZ728623A (en) | Novel sulfonylaminobenzamide compounds as anthelmintics | |
PH12016501183A1 (en) | Novel compound for treatment of severe hypoglycemia | |
MX350430B (es) | Proceso para preparar compuestos acido 4-amino-5-bifenil-4-il-2-hi droximetil-2-metil-pentanoico. | |
MX2019002017A (es) | Derivados de sofosbuvir para el tratamiento de la hepatitis c. | |
PH12016501184A1 (en) | Novel compound for treatment of severe hypoglycemia | |
PH12016501182A1 (en) | Novel compound for treatment of severe hypoglycemia | |
MX2016010268A (es) | Pirimidinimidazolaminas como modulares de actividad de cinasa. | |
GB2564185A (en) | Process for the preparation of derivatives of benzodioxole | |
MX2016002198A (es) | Proceso para la preparación de un compuesto. | |
MX2016009448A (es) | (hetero)aril-imidazoles/pirazoles para el tratamiento de trastornos neurologicos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |